Literature DB >> 2440306

The use and limitations of endocervical Gram stains and mucopurulent cervicitis as predictors for Chlamydia trachomatis in female adolescents.

B Moscicki, M A Shafer, S G Millstein, C E Irwin, J Schachter.   

Abstract

We evaluated the presence of polymorphonuclear cells on endocervical Gram stains and clinical indices of cervicitis as predictors of Chlamydia trachomatis infection in 193 sexually active female adolescents; 148 (77%) subjects had no complaints. C. trachomatis was isolated from 34 (18%) subjects. The incidence of C. trachomatis differed by race: it was isolated from 30% of black subjects and 7% of nonblack subjects. Polymorphonuclear cells on Gram stains were found to be associated with the presence of C. trachomatis (chi 2 = 33.2, p less than 0.0001). The sensitivity, specificity, and positive predictive value for polymorphonuclear cells to predict the presence of C. trachomatis were 91% (31/34), 65% (103/159), and 36% (31/87), respectively. When examined by ethnicity, polymorphonuclear cells remained significantly associated with C. trachomatis for black subjects (chi 2 = 24.3, p less than 0.001) but not for nonblack subjects (chi 2 = 2.49, p less than 0.1). Mucopurulent discharge, friability, or erythema-edema of ectopy were not reliable indicators for C. trachomatis. Endocervical Gram stains alone are useful to identify populations at risk for C. trachomatis infection. Caution must be advised when interpreting data from different population groups because of the variability in C. trachomatis prevalence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440306     DOI: 10.1016/s0002-9378(87)80347-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Use of sequential enzyme immunoassay and direct fluorescent antibody tests for detection of Chlamydia trachomatis infections in women.

Authors:  J R Schwebke; W E Stamm; H H Handsfield
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

Review 2.  The challenges of collecting data on race and ethnicity in a diverse, multiethnic state.

Authors:  Bliss Kaneshiro; Olga Geling; Kapuaola Gellert; Lynnae Millar
Journal:  Hawaii Med J       Date:  2011-08

3.  Secret cervicitis?

Authors:  D M Patrick
Journal:  CMAJ       Date:  1998-01-13       Impact factor: 8.262

4.  Effect of endocervical specimen quality on detection of Chlamydia trachomatis and on the incidence of false-positive results with the Chlamydiazyme method.

Authors:  J A Kellogg; J W Seiple; C L Murray; J S Levisky
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

5.  Endocervical Chlamydia trachomatis infection in Canadian adolescents.

Authors:  E G Hughes; J Mowatt; J E Spence
Journal:  CMAJ       Date:  1989-02-01       Impact factor: 8.262

6.  A new diagnostic index for predicting cervical infection with either Chlamydia trachomatis or Neisseria gonorrhoeae.

Authors:  G E Rosenthal; G Mettler; S Pare; M Riegger; M Ward; C S Landefeld
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

7.  Screening for cervical Chlamydia trachomatis infections in two Dutch populations.

Authors:  E A Thewessen; W I van der Meijden; H J Doppenberg; P G Mulder; J H Wagenvoort; E Stolz; M F Michel
Journal:  Genitourin Med       Date:  1990-10

8.  Chlamydial cervicitis: testing the practice guidelines for presumptive diagnosis.

Authors:  J Sellors; M Howard; L Pickard; D Jang; J Mahony; M Chernesky
Journal:  CMAJ       Date:  1998-01-13       Impact factor: 8.262

9.  Periodic health examination, 1996 update: 2. Screening for chlamydial infections. Canadian Task Force on the Periodic Health Examination.

Authors:  H D Davies; E E Wang
Journal:  CMAJ       Date:  1996-06-01       Impact factor: 8.262

10.  Quantitative culture of endocervical Chlamydia trachomatis.

Authors:  R C Barnes; B P Katz; R T Rolfs; B Batteiger; V Caine; R B Jones
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.